Abstract 439P
Background
Ewing’s sarcoma and osteosarcoma have high incidence in teenage and young adults (TYA) with age range(15-29 years). This study investigated the epidemiology of cancers among TYA population,with a special emphasis on Ewing’s sarcoma, evaluating theimpact of symptom delay and system delay variables on the patient outcomes.
Methods
This was a single-center, retrospective cross-sectional study conducted between June 2015 and March 2020 on TYA patients with a confirmed diagnosis of cancer. TYA patients registered with Ewing’s sarcoma were selected for the study using a non-probability sampling technique. The symptom delay was defined as >1 month duration from the first symptom to the consultation by primary care physician (PCP). The system delay was defined as >1 month duration from initial consultation by PCP to referring the patient to a dedicated cancer center.
Results
Our study gives a comprehensive overview of cancer epidemiology among TYA patients. Our observation is that 7.35% (450/6120) of our cancer patients are TYAs. Ewing’s sarcoma was found in 8.88% (40/450) of all the TYA cancer patients.Symptom delay was noted among 65.0% of patients and system delay occurred among 57.5% of patients. We observed that symptom delay and system delay at presentation had a significant impact on the patient outcome in terms of increased metastasis and reduced progression free survival. Patients with large tumor volume (>100 cc) had poor Progression Free Survival (PFS), showing a strong negative correlation between tumor volume and PFS. Mean five-year PFS for patients with no detectable metastatic disease at diagnosis was significantly better than for those with metastases (59m vs. 19m, respectively; P<.001). Table: 439P
Correlation of PFS with clinical variables
Parameter | Variable | n | PFS (months) Mean ±SD | p-value | ||
Localized Disease | No | 15 | 18.93±8.74 | p<0.001 | ||
Yes | 25 | 59.28±16.09 | ||||
Symptom Delay in Survived | No | 14 | 69.07±10.12 | p<0.001 | ||
Yes | 16 | 40.69±15.19 | ||||
System Delay in Survived | No | 16 | 66.94±12.20 | p<0.001 | ||
Yes | 14 | 39.07±14.62 |
Conclusions
Ewing’s sarcoma should be considered the prototype of a TYA cancer. Efforts in improving access to healthcare facilities, education of primary healthcare physicians, pediatricians and orthopedic surgeons is of paramount importance to facilitate an early diagnosis and establish care pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06